APTO - Aptose initiates dosing of CG-806 in patients with acute myeloid leukemia

Aptose Biosciences ([[APTO]] +2.8%) announces dosing of the first patient with acute myeloid leukemia in a Phase 1 a/b clinical study with CG-806, the company’s oral kinase inhibitor.The investigational drug is the only known clinical agent that potently inhibits both FLT3 and BTK, giving it broad therapeutic potential across the spectrum of lymphoid and myeloid hematologic malignancies. “The 450mg starting dose in AML patients was selected because that dose, when administered to CLL patients being treated in a separate Phase 1 a/b trial, appeared safe, well tolerated and achieved plasma exposure levels that effectively inhibited phospho-FLT3 activity, which is a key driver of AML.” said William G. Rice, Ph.D., Chairman, President and CEO.

For further details see:

Aptose initiates dosing of CG-806 in patients with acute myeloid leukemia